Table 1.
Participant characteristics
| Participant characteristics |
Furosemide naïve |
Chronic furosemide |
p-value |
|---|---|---|---|
| (n = 23) | (n = 15) | ||
| Age (years) |
68 ± 8 |
69 ± 10 |
0.49 |
| Race |
|
|
0.28 |
| White (%) |
78 |
67 |
|
| African American (%) |
22 |
33 |
|
| Gender (% male) |
35 |
40 |
0.65 |
| Body mass index (kg/m2) |
29.4 ± 6.5 |
30.3 ± 7.1 |
0.56 |
| GFR (mL/min/1.73 m2) |
60.1 ± 31.6 |
44.6 ± 14.7 |
0.005* |
| Renal artery stenosis (mean,%) |
|
|
|
| Left |
26 |
24 |
0.70 |
| Right |
26 |
21 |
0.82 |
| Renal blood flow (mean, ml/min) |
|
|
|
| Left |
187 |
127 |
0.17 |
| Right |
231 |
196 |
0.50 |
| Chronic kidney disease stage (n) |
|
|
0.01* |
| Stage 1 (GFR > 90) |
5 (22%) |
0 (0%) |
|
| Stage 2 (GFR 60-89) |
5 (22%) |
2 (13%) |
|
| Stage 3 (GFR 30-59) |
9 (39%) |
9 (60%) |
|
| Stage 4 (GFR 15-29) |
4 (17%) |
4 (27%) |
|
| Stage 5 (GFR < 15) |
0 (0%) |
0 (0%) |
|
| Hypertension diagnosis (%) |
91 |
100 |
0.25 |
| Number of antihypertensive meds (n) |
2.7 ± 1.6 |
4.3 ± 1.0 |
0.0001* |
| Hemoglobin (g/dL) |
12.7 ± 2.3 |
12.1 ± 1.8 |
0.25 |
| Diabetes diagnosis (%) |
30 |
60 |
0.01* |
| Patients on statin therapy (%) |
65 |
73 |
0.45 |
| Patients on ACEI’s or ARB’s (%) | 65 | 33 | 0.006* |
Mean ± SE are displayed. GFR glomerular filtration rate, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers. *represents p<0.05.